Clinical practice implications of ENZAMET study results in mHSPC

Ian D. Davis, MBBS, PhD, FRACP, FAChPM, of the Eastern Health Clinical School at Monash University in Box Hill, Australia, interprets the clinical significance of the findings of the ENZAMET study for the management of patients with metastatic hormone-sensitive prostate cancer (mHSPC). At the 2022 ASCO Annual Meeting, Davis presented the abstract, “Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in mHSPC.”